摘要
近年来癌症治疗领域的巨大进步之一是免疫治疗的出现。免疫疗法,尤其是免疫检查点抑制剂,已经在实体瘤例如黑素瘤,乳腺癌和肺癌的临床前模型和临床试验中显示出有希望的结果。针对免疫微环境的治疗策略也已经应用于血液恶性肿瘤,如多发性骨髓瘤(MM),其特征是主要在骨髓(BM)中恶性浆细胞的克隆增殖的浆细胞瘤形成。 MM与细胞和体液免疫缺陷相关,表明疾病从前体状态的演变(未确定意义的单克隆丙种球蛋白(MGUS)和阴燃MM(sMM))与促进免疫逃逸和肿瘤的免疫抑制环境相关联生长。尽管治疗有显着进展,但MM主要是不治之症。因此,开发不仅靶向MM克隆本身而且针对MM免疫微环境的新型治疗剂是至关重要的。然而,BM微环境的复杂性和肿瘤细胞克隆的异质性使得开发MM的适当免疫治疗成为一项艰巨的任务。在本文中,我们回顾了疾病进展期间恶性浆细胞与骨髓免疫微环境之间相互作用的现有知识
关键词: 多发性骨髓瘤,脊髓,MDSC,效应T细胞,NK细胞,DCs,巨噬细胞检查点抑制剂。
图形摘要
Current Cancer Drug Targets
Title:Multiple Myeloma and the Immune Microenvironment
Volume: 17 Issue: 9
关键词: 多发性骨髓瘤,脊髓,MDSC,效应T细胞,NK细胞,DCs,巨噬细胞检查点抑制剂。
摘要: One of the great advances in the field of cancer therapy in recent years is the emergence of immune therapies. Immune therapies, especially immune checkpoint inhibitors, have shown promising results in pre-clinical models and clinical trials of solid tumors, such as melanoma, breast cancer and lung cancer. Therapeutic strategies targeting the immune microenvironment have also been applied to hematological malignancies such as multiple myeloma (MM), a plasma cell neoplasia characterized by clonal proliferation of malignant plasma cells mainly in the bone marrow (BM). MM is associated with both cellular and humoral immune deficiencies, indicating that the evolution of the disease from a precursor state (monoclonal gammopathy of undetermined significance (MGUS) and smoldering MM (sMM)) is associated with an immunosuppressive milieu that fosters immune escape and tumor growth. Despite significant advances in treatment, MM is mostly an incurable disease. Therefore, it is vital to develop novel therapeutic agents that not only target the MM clone itself but also the MM immune microenvironment. However, the complexity of the BM microenvironment and heterogeneity of tumor cell clones make it a difficult task for developing appropriate immune therapies of MM. In this article, we review the current knowledge of the interaction between malignant plasma cells and the bone marrow immune microenvironment during disease progression.
Export Options
About this article
Cite this article as:
Multiple Myeloma and the Immune Microenvironment, Current Cancer Drug Targets 2017; 17 (9) . https://dx.doi.org/10.2174/1568009617666170214102301
DOI https://dx.doi.org/10.2174/1568009617666170214102301 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recognition and Function of HumanγδT Cells: Application for Tumor Immunotherapy
Current Immunology Reviews (Discontinued) p53 as the Focus of Gene Therapy: Past, Present and Future
Current Drug Targets A Review on Recent Technologies and Patents on Silica Nanoparticles for Cancer Treatment and Diagnosis
Recent Patents on Drug Delivery & Formulation Clinical Experience with Antiangiogenic Therapy in Leukemia
Current Cancer Drug Targets Dual Cyclooxygenase and Carbonic Anhydrase Inhibition by Nonsteroidal Anti-Inflammatory Drugs for the Treatment of Cancer
Current Medicinal Chemistry Lipid-based Nanocarriers As An Alternative for Oral Delivery of Poorly Water- Soluble Drugs: Peroral and Mucosal Routes
Current Medicinal Chemistry Editorial [Hot Topic: Adrenergic Receptors as Novel Targets for Cancer Therapy (Guest Editors: D.G. Powe and F. Entschladen)]
Current Cancer Therapy Reviews Bamboo a Supplement to Human Health: A Comprehensive Review on its Ethnopharmacology, Phytochemistry, and Pharmacological Activity
The Natural Products Journal Cancer Stem Cells and their Management in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Chemically Functionalized Carbon Nanotubes: Emerging Vectors for Cell Therapy
Mini-Reviews in Medicinal Chemistry Past, Present and Future of Nutrigenomics and its Influence on Drug Development
Current Drug Discovery Technologies New Benzothiazole/thiazole-Containing Hydroxamic Acids as Potent Histone Deacetylase Inhibitors and Antitumor Agents
Medicinal Chemistry Molecular Aspects of Stromal-Parenchymal Interactions in Malignant Neoplasms
Current Molecular Medicine 3-Substituted-3-hydroxy-2-oxindole, an Emerging New Scaffold for Drug Discovery with Potential Anti-Cancer and other Biological Activities
Current Bioactive Compounds Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Pain Biomarkers in Cancer: An Overview
Current Pharmaceutical Design Chemopreventive Effects of Conjugated Linolenic Acids (CLN) Occurring in Plant Seed Oils
Current Nutrition & Food Science 64Cu Labeled AmBaSar-RGD2 for micro-PET Imaging of Integrin αvβ3 Expression
Current Radiopharmaceuticals Nutrition in Adult Patients with Inflammatory Bowel Disease
Current Drug Targets Targeting Glioblastoma: The Current State of Different Therapeutic Approaches
Current Neuropharmacology